{"entity":{"id":"nct05716087","kind":"trial","name":"A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma","aka":[],"tldr":"A phase 2 trial of Rocbrutinib in mantle cell lymphoma, run by Guangzhou Lupeng Pharmaceutical Company LTD., active and no longer recruiting.","summary":"A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT05716087 by Guangzhou Lupeng Pharmaceutical Company LTD., with 62 participants planned, started 2023-02-21 and due to reach its primary completion in 2024-12-05. Interventions recorded: Rocbrutinib. Conditions listed: Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05716087","url":"https://clinicaltrials.gov/study/NCT05716087"}],"tags":["ctgov-ingest"],"related":[],"cancers":["mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["rocbrutinib"],"companies":["lupeng-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05716087","phase":"2","setting":"An Open Label, Single Arm, Multicenter Phase II Study of the Efficacy and Safety of Rocbrutinib Monotherapy for Recurrent or Refractory Mantle Cell Lymphoma","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","participation":[{"nct":"NCT05716087","source":"https://clinicaltrials.gov/study/NCT05716087","fetchedAt":"2026-10-07T16:53:52.193Z","studySha256":"f85bd26e4a7c0d6fec786ac32516958a43a2182a7b15394b858bfa62f8fe7ab3","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-01-15","leadSponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":62,"enrolmentType":"ESTIMATED","siteCount":43,"recruitingSiteCount":0,"countries":["China"]}],"started":"2023-02-21","startedType":"actual","enrolled":62,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05716087/","neighbours":{"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"drug":[{"id":"rocbrutinib","kind":"drug","name":"Rocbrutinib","route":"/drugs/rocbrutinib/"}],"company":[{"id":"lupeng-pharmaceuticals","kind":"company","name":"Lupeng Pharmaceuticals","route":"/companies/lupeng-pharmaceuticals/"}]}}